Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Tyra Biosciences's TYRA-200?
TYRA-200 is a small molecule commercialized by Tyra Biosciences, with a leading Phase I program in Solid Tumor. According to...
TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
TYRA-200 is under clinical development by Tyra Biosciences and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to...
TYRA-200 by Tyra Biosciences for Solid Tumor: Likelihood of Approval
TYRA-200 is under clinical development by Tyra Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Tyra Biosciences's TYRA-200?
TYRA-200 is a small molecule commercialized by Tyra Biosciences, with a leading Phase I program in Bile Duct Cancer (Cholangiocarcinoma)....